Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is n...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/1423683 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555430138609664 |
|---|---|
| author | Kayoko Waki Kouichiro Kawano Naotake Tsuda Kimio Ushijima Kyogo Itoh Akira Yamada |
| author_facet | Kayoko Waki Kouichiro Kawano Naotake Tsuda Kimio Ushijima Kyogo Itoh Akira Yamada |
| author_sort | Kayoko Waki |
| collection | DOAJ |
| description | High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is no information on HMGB1 levels in cancer patients treated with peptide vaccination. In the present study, we investigated the plasma levels of HMGB1 during personalized peptide vaccination in patients with recurrent ovarian cancer. Frozen plasma samples of 39 patients from previously conducted clinical trials were used in this study. HMGB1 levels were decreased after the 1st cycle of vaccination from their prevaccination levels. However, no correlation was observed between HMGB1 and overall survival (OS). The correlation between plasma HMGB1 levels and other biomarker levels was further analyzed by scatter plot, revealing that HMGB1 levels after the 1st cycle of vaccination were significantly correlated with myeloid-derived suppressor cell (MDSC) frequency after the 1st cycle of vaccination (r=0.357, p=0.032). Chi-square test showed that epitope spreading was significantly related with changes of HMGB1 (p=0.030). These results suggest that plasma HMGB1 is a possible biomarker for cancer vaccine therapy, although direct correlation with OS has not been obtained. This trial is registered with Clinical Trial Registry under trial numbers UMIN000003083 and UMIN000001482. |
| format | Article |
| id | doaj-art-a2ee2e5b3ee947799ff5258af036c0ed |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-a2ee2e5b3ee947799ff5258af036c0ed2025-02-03T05:48:15ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/14236831423683Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian CancerKayoko Waki0Kouichiro Kawano1Naotake Tsuda2Kimio Ushijima3Kyogo Itoh4Akira Yamada5Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, JapanDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, JapanDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, JapanDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, JapanCancer Vaccine Center, Kurume University, Kurume, JapanCancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, JapanHigh-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is no information on HMGB1 levels in cancer patients treated with peptide vaccination. In the present study, we investigated the plasma levels of HMGB1 during personalized peptide vaccination in patients with recurrent ovarian cancer. Frozen plasma samples of 39 patients from previously conducted clinical trials were used in this study. HMGB1 levels were decreased after the 1st cycle of vaccination from their prevaccination levels. However, no correlation was observed between HMGB1 and overall survival (OS). The correlation between plasma HMGB1 levels and other biomarker levels was further analyzed by scatter plot, revealing that HMGB1 levels after the 1st cycle of vaccination were significantly correlated with myeloid-derived suppressor cell (MDSC) frequency after the 1st cycle of vaccination (r=0.357, p=0.032). Chi-square test showed that epitope spreading was significantly related with changes of HMGB1 (p=0.030). These results suggest that plasma HMGB1 is a possible biomarker for cancer vaccine therapy, although direct correlation with OS has not been obtained. This trial is registered with Clinical Trial Registry under trial numbers UMIN000003083 and UMIN000001482.http://dx.doi.org/10.1155/2017/1423683 |
| spellingShingle | Kayoko Waki Kouichiro Kawano Naotake Tsuda Kimio Ushijima Kyogo Itoh Akira Yamada Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer Journal of Immunology Research |
| title | Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer |
| title_full | Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer |
| title_fullStr | Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer |
| title_full_unstemmed | Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer |
| title_short | Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer |
| title_sort | plasma levels of high mobility group box 1 during peptide vaccination in patients with recurrent ovarian cancer |
| url | http://dx.doi.org/10.1155/2017/1423683 |
| work_keys_str_mv | AT kayokowaki plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer AT kouichirokawano plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer AT naotaketsuda plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer AT kimioushijima plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer AT kyogoitoh plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer AT akirayamada plasmalevelsofhighmobilitygroupbox1duringpeptidevaccinationinpatientswithrecurrentovariancancer |